Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company nLife Therapeutics S.L.
DescriptionA neuronal selective antisense oligonucleotide against alpha synuclein (SNCA)
Molecular Target Alpha synuclein (SNCA)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPreclinical
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today